Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy
Public ClinicalTrials.gov record NCT01039376. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Maintenance Treatment Versus no Further Treatment in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) Who Have Responded to Induction Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to determine if maintenance therapy with ofatumumab would prolong remission in patients with CLL who have responded to second or third line treatment. This study would also evaluate the safety of ofatumumab maintenance compared to observation (the current standard of care). This study was co-developed with the HOVON and NORDIC CLL group and would be conducted as a collaborative effort with GSK.
Study identification
- NCT ID
- NCT01039376
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 480 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 6, 2010 (Actual)
- Primary completion
- Feb 20, 2017 (Actual)
- Completion
- Jun 26, 2018 (Actual)
- Last update posted
- Jul 30, 2019
2010 – 2018
United States locations
- U.S. sites
- 43
- U.S. states
- 24
- U.S. cities
- 40
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Gilbert | Arizona | 85234 | — |
| Novartis Investigative Site | Tucson | Arizona | 85710 | — |
| Novartis Investigative Site | Tucson | Arizona | 85715 | — |
| Novartis Investigative Site | Jonesboro | Arkansas | 72401 | — |
| Novartis Investigative Site | Berkeley | California | 94704 | — |
| Novartis Investigative Site | La Verne | California | 91750 | — |
| Novartis Investigative Site | Sacramento | California | 95815 | — |
| Novartis Investigative Site | Sacramento | California | 95816 | — |
| Novartis Investigative Site | San Pablo | California | 94806 | — |
| Novartis Investigative Site | Hartford | Connecticut | 06105 | — |
| Novartis Investigative Site | Gainesville | Florida | 32610 | — |
| Novartis Investigative Site | Lake Worth | Florida | 33461 | — |
| Novartis Investigative Site | Orlando | Florida | 32806 | — |
| Novartis Investigative Site | Pembroke Pines | Florida | 33028 | — |
| Novartis Investigative Site | West Palm Beach | Florida | 33401 | — |
| Novartis Investigative Site | Macon | Georgia | 31201 | — |
| Novartis Investigative Site | Savannah | Georgia | 31405 | — |
| Novartis Investigative Site | Post Falls | Idaho | 83854 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46202 | — |
| Novartis Investigative Site | Iowa City | Iowa | 52242 | — |
| Novartis Investigative Site | Westwood | Kansas | 66205 | — |
| Novartis Investigative Site | Metairie | Louisiana | 70006 | — |
| Novartis Investigative Site | Cumberland | Maryland | 21502 | — |
| Novartis Investigative Site | Hagerstown | Maryland | 21742 | — |
| Novartis Investigative Site | Worcester | Massachusetts | 01655 | — |
| Novartis Investigative Site | Detroit | Michigan | 48202 | — |
| Novartis Investigative Site | Springfield | Missouri | 65807 | — |
| Novartis Investigative Site | St Louis | Missouri | 63110 | — |
| Novartis Investigative Site | Henderson | Nevada | 89014 | — |
| Novartis Investigative Site | New Brunswick | New Jersey | 08901 | — |
| Novartis Investigative Site | Albuquerque | New Mexico | 87110 | — |
| Novartis Investigative Site | Albuquerque | New Mexico | 87131 | — |
| Novartis Investigative Site | Mineola | New York | 11501 | — |
| Novartis Investigative Site | Rochester | New York | 14621 | — |
| Novartis Investigative Site | Chapel Hill | North Carolina | 27599-7305 | — |
| Novartis Investigative Site | Durham | North Carolina | 27710 | — |
| Novartis Investigative Site | Philadelphia | Pennsylvania | 19104 | — |
| Novartis Investigative Site | Greenville | South Carolina | 29601 | — |
| Novartis Investigative Site | Chattanooga | Tennessee | 37421 | — |
| Novartis Investigative Site | Knoxville | Tennessee | 37916 | — |
| Novartis Investigative Site | Memphis | Tennessee | 38120 | — |
| Novartis Investigative Site | Orem | Utah | 84058 | — |
| Novartis Investigative Site | Salt Lake City | Utah | 84106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 160 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01039376, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 30, 2019 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01039376 live on ClinicalTrials.gov.